Other Compounds
Melanotan-2
Also published as MT-2, MT-II
A cyclic analogue of alpha-MSH that is active at MC1, MC3, MC4 and MC5 receptors rather than MC1 alone. That lack of selectivity is what produced both its wider effects and its safety record.
Where it came from
Developed alongside Melanotan-1 at the University of Arizona. Bremelanotide, an approved medicine for hypoactive sexual desire disorder, is a metabolite of it.
What the literature examines
- Melanocortin receptor pharmacology across MC1, MC3, MC4 and MC5
- Eumelanin synthesis and pigmentation
- Erectile response and sexual behaviour, in early human studies
- Appetite suppression through MC4 receptor activity
State of the evidence
Early human studies exist. It was never taken through to registration. Its metabolite bremelanotide was, in a different indication.
What a buyer should know
This compound has an unusually well documented adverse event record for something never approved: nausea and flushing, spontaneous erection, and multiple published case reports of new or changing melanocytic naevi and of melanoma following use. National regulators in the UK, Australia and elsewhere have issued specific public warnings about it. It is also the compound in this catalogue most likely to draw regulatory attention to a storefront that markets it loosely.
Handling and stability
Lyophilised, water soluble, light sensitive, cold chain.
Read it yourself
We do not publish a curated citation list, because a hand picked list of papers is a sales tool. These links run a live query against the public databases, so you see everything, including the results that do not suit us.
Supplied for laboratory research use only. Nothing on this page is a dose, a protocol or a claim of effect in humans, and nothing here is medical advice. Read our research use policy.